These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34626090)

  • 1. Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension.
    Hanaoka H; Ishigaki S; Takei H; Hiramoto K; Saito S; Kondo Y; Kikuchi J; Kaneko Y; Takeuchi T
    Int J Rheum Dis; 2021 Nov; 24(11):1419-1426. PubMed ID: 34626090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
    Pan J; Lei L; Zhao C
    Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Right atrial function for the prediction of prognosis in connective tissue disease-associated pulmonary arterial hypertension: a study with two-dimensional speckle tracking.
    Bai Y; Yang J; Liu J; Ning H; Zhang R
    Int J Cardiovasc Imaging; 2019 Sep; 35(9):1637-1649. PubMed ID: 31037473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
    Cansu DÜ; Korkmaz C
    Clin Rheumatol; 2023 Oct; 42(10):2601-2610. PubMed ID: 36396789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized pilot study on the effect of niacin on pulmonary arterial pressure.
    McNamara MJ; Sayanlar JJ; Dooley DJ; Srichai MB; Taylor AJ
    Trials; 2015 Nov; 16():530. PubMed ID: 26590128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry.
    Kang KY; Jeon CH; Choi SJ; Yoon BY; Choi CB; Lee CH; Suh CH; Lee CW; Cho CS; Nam EJ; Koh EM; Kim HY; Choi HJ; Kim HA; Jun JB; Lee J; Kim J; Ji JD; Min JK; Kim KJ; Shin K; So MW; Kwon SR; Kim SK; Nah SS; Kwok SK; Lee SK; Lee SW; Park SH; Park W; Park YB; Lee YH; Lee SS; Yoo DH
    Int J Rheum Dis; 2017 Sep; 20(9):1227-1236. PubMed ID: 26214170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension.
    Wright L; Dwyer N; Wahi S; Marwick TH
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 1):2103-2111. PubMed ID: 30343091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension in connective tissue diseases: an update.
    Aithala R; Alex AG; Danda D
    Int J Rheum Dis; 2017 Jan; 20(1):5-24. PubMed ID: 28205373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
    Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
    Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence.
    Papathanasiou M; Ruhparwar A; Kamler M; Rassaf T; Luedike P
    Pharmacol Ther; 2020 Oct; 214():107619. PubMed ID: 32599009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease.
    Suzuki Y; Nagaoka T; Terayama Y; Nagata Y; Yoshida T; Tsutsumi T; Kuriyama S; Matsushita M; Joki Y; Takasu K; Konishi H; Takahashi K
    Respir Investig; 2024 Jan; 62(1):167-175. PubMed ID: 38142548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pulmonary hypertension with left heart disease: a concise review.
    Desai A; Desouza SA
    Vasc Health Risk Manag; 2017; 13():415-420. PubMed ID: 29158679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
    Castaldi B; Bordin G; Padalino M; Cuppini E; Vida V; Milanesi O
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29193758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.
    Peacock AJ; Crawley S; McLure L; Blyth KG; Vizza CD; Poscia R; Francone M; Iacucci I; Olschewski H; Kovacs G; Vonk Noordegraaf A; Marcus JT; van de Veerdonk MC; Oosterveer FP
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):107-14. PubMed ID: 24173272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
    Wang L; Jin YZ; Zhao QH; Jiang R; Wu WH; Gong SG; He J; Liu JM; Jing ZC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3353-3360. PubMed ID: 29200842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.